



ETHICS of EMERGING TECHNOLOGIES

SCIENTIFIC FACTS AND
MORAL CHALLENGES

THOMAS F. BUDINGER - MIRIAM D. BUDINGER

Contents

Preface xiii

1 Ethical Principles, Reasoning, and Decision Making 1

Introduction	1
Designing Solutions to Ethical Dilemmas	3
Evolution of Ethical Principles	6
Virtue Ethics	7
Justice Ethics	8
Rules Ethics	10
Rights Ethics	10
Duty Ethics	11
Modern Duty Ethics and Ross's Prima Facie Duties	14
Utilitarianism	17
Analysis of Duty Ethics vs. Utilitarianism	20
Autonomy vs. Utilitarianism	21
Utilitarianism vs. Justice: Allocation of Limited Resources	23
Other Moral Theories	24
Cultural Relativism	24
Pragmatism	25
Pluralism	25
Subjectivism	25
Minimum Conception of Morality	26
Other Concepts and Ideologies	26
Principles That Guide Human Experimentation	27
Dangers of Expediency and the Slippery Slope Theory	30
Learning Values and Cheating in Life	31
Synopsis of Tools for Resolving Ethical Dilemmas	32
Chapter Summary	33
References	34
Additional Reading	36
Problem Set	37

2 Ethics in Scientific Research 39

Introduction	39
Definition of Scientific Misconduct	40
Categories of Scientific Misconduct	41

Unethical Conduct by Researchers	41
Ethical Transgressions by Authors	42
Ethical Transgressions by Reviewers	44
Examples of Scientific Misconduct	45
Responsible Authorship	54
Guidelines for Authorship for Bioscience Journals	55
National Academy of Sciences Guidance on Responsible Authorship	56
Practical Guidelines for Assigning Authorship	57
Ranking of Authors	58
Stealing and Copyright	59
Plagiarism	59
Motives for Scientific Misconduct and Countermeasures	61
Discovery of Scientific Misconduct and Whistleblowing	62
Criteria for Whistleblowing	63
Consequences of Being Accused of Scientific Misconduct, and Protection When Accused of Scientific Misconduct	65
Whistleblower Protection Act (WPA)	65
Approaches to Scientific Misconduct: What Should Be Done?	66
Responsibilities of Individual Researchers	66
Responsibilities of Government, Universities, and Research Institutions	66
Conflict of Interest as a Category of Scientific Misconduct	67
Managing Conflicts of Interest	68
Conflicts between Goals of Commercialism and the Tenets of Academia	69
Chapter Summary	70
References	71
Additional Reading	74
Appendix	74
Appendix 2.1: Federal Policy on Research Misconduct	74
Problem Set	78

3 Information Technology Ethics 81

Introduction	81
The Benefits and Problems Generated by the Information Technologies	84
Benefits	84
Problems Associated with IT	85
Invasion of Privacy Due to Faulty Engineering of Computer Systems and Software Programs	85
Risks to Privacy by Outsourcing Private Information to Other Countries	88
Collection, Storage, Selling, and Unauthorized Use of Personal Information	88
Loss of Privacy by Monitoring	89
Ethics of Camera Surveillance in Public Places	91
Unauthorized Use of Intellectual Property (IP)	91
Hacking and Hoaxes	93
Plagiarism	94
Journalism on the Internet	94
Theft, Deception, and Fraud on the Internet	95
Censorship in Internet Communications	95
Spam	97
Availability of Information Technologies	97
Chapter Summary	98
References	99
Additional Reading	100
Appendix	100
Appendix 3.1. Committee for the Protection of Human Subjects: Security of Research Subjects' Personally Identifiable Data Held by Researchers (Excerpts from http://chps.berkeley.edu)	100
Problem Set	102

4 Business Ethics 104

Introduction	104
Historical Background	106
Design Strategy for Corporate Ethical Dilemmas	108
Corporate Practices Challenge Ethical Theories	110
Differences in Corporate Tactics	111
Credo vs. Vision Statement	113
Guidelines and Pitfalls of Corporate Strategies	114
Conflicts in Ethical Theories	115
Beneficence to the Community vs. Duty to the Stockholders	116
Utilitarianism vs. Justice	117

Duty vs. Justice and Virtue	119
Non-Maleficance vs. Utilitarianism	120
Virtue vs. Duty	122
Corporate Responsibilities	126
Responsibilities to Employees	126
Ethnic, Religious, and Sexual Harassment Issues in the Workplace	126
Responsibilities to the Public	128
Responsibilities in Business with a Foreign Country	129
Responsibilities to the Ecosystem	129
The Ethics of the Professional Employee	130
Confidentiality	130
Confidentiality When Changing Jobs	134
Loyalty vs. Duty to Report Misdeeds	135
Whistleblower Responsibility of Corporate Employees	135
Obligations to Report Safety Violations or Threats to the Public	137
Conflicts of Interest	137
Federal Reaction to Corporate Fraud	138
Chapter Summary	138
References	139
Additional Reading	142
Web Sites Helpful for Business Ethics Issues	143
Appendix	143
Appendix 4.1 Some Strategic Rules from Sun Tzu (Michaelson 2001)	143
Problem Set	144

5 Environmental Ethics 147

Introduction	147
Current Energy Production and Use	150
Predicted Energy Needs for the Future	151
Transportation: the Greatest Consumer of Fossil Fuels	153
Energy Use by Communications Technologies	154
Alternative Energy Technologies	155
Fuel Cells	155
Nuclear Reactors	155
Nuclear Fusion as a Source of Energy	158
Wind Production of Energy	160
Hydroelectric Production and Storage of Energy	161
Solar Source of Electricity and Fuel	161

Moral, Spiritual, and Ideological Perspectives on the Environment	162		
Using vs. Saving the Environment	163		
The Dimensions of the Moral Community	163		
Moral Theories and the Environment	164		
Religious or Spiritual Approaches to the Environment	165		
Ideological Approaches to the Environment	167		
Anthropocentrism	167		
Biocentrism	167		
Ecocentrism	168		
Deep Ecology	168		
Ecofeminist Approach to the Environment	168		
Modern Pantheist Approach	169		
A Conceptual Structure for Environmental Ethics			
Based on Relative Value	169		
The Global Environment	171		
Responsibility for Technologies We Create	171		
The Tragedy of the Commons	172		
Where We Go from Here	172		
Societal Efforts to Prevent Environment Degradation and Promote Sustainability	173		
Summary of International Conferences to Protect and Sustain the Environment	174		
The Vienna Convention on the Protection of the Ozone Layer, Vienna, Austria, 1985, and the Montreal Protocol on Substances That Deplete the Ozone Layer, Montreal, Canada, 1987	174		
U.N. Conference on Environment and Development, Rio de Janeiro, 1992	175		
U.N. Framework Convention on Climate Change, Kyoto, Japan, 1997	176		
United Nations Millennium Summit, New York, New York, 2000	176		
United Nations World Summit on Sustainable Development, Johannesburg, South Africa, 2002	177		
U.N. World Environment Conference of Mayors, San Francisco, California, June 2005	178		
The G8 Annual Conferences	179		
Chapter Summary	179		
References	180		
Additional Reading	183		
Appendix	184		
Appendix 5.1 Physical Dimensions and Units	184		
Problem Set	185		
		6 Ethics of Genetically Modified Organisms	186
		<hr/>	
		Introduction	186
		Processes Involved in Genetic Engineering of Plants and Animals	188
		Genetic Modification of Plants without the Introduction of Foreign DNA	189
		Stimulation of Mutations in Plants by Chemicals or Ionizing Radiation	189
		Stimulation of Transposons to Induce Changes in the Plant Genome by Stress	189
		In Situ Microsurgery to Stimulate Transposon-Induced Changes in Plants and Animals	190
		Genetic Modification of Plants and Animals by Transfer of Foreign DNA	191
		Genetic Modification by Microinjection of DNA into Cells	191
		Genetic Modification by Gene Transfer Using Plasmids and Bacteria	192
		Biolistic Impaction Method of Gene Transfer into Plants	193
		Growth in the Use of GMO Products	194
		Benefits and Risks of GMOs	195
		Benefits	195
		Risks of Genetically Modified Organisms	196
		Concerns about Physical Escape of GMOs into the Wild	197
		Concerns about the Biology of Horizontal Gene Transfer	198
		Concerns about Biodiversity and Perturbations in Biologic Evolution	200
		Concerns about Marker Genes and Other Modifications	200
		Concerns about Genetically Modified Animals	200
		Concerns about Who Will Benefit	201
		Concerns about GMO Labeling	202
		Cumulative Effect of Concerns about GMOs	203
		Ongoing Efforts to Evaluate and Provide Information on GMOs	204
		U. S. Government Oversight and Regulations	205
		FDA's Biotechnology Policy	205
		USDA/APHIS Regulation of Bioengineered Plants	206

Environmental Protection Agency Functions 206
 Involvement of the U.S. Congress 206
 The United States vs. the European Union Stance on
 GMOs 207
 International Regulatory Approach to GMOs: U.N.
 Cartagena Protocol on Biosafety 207
 Ethical Issues 208
 Chapter Summary 213
 References 214
 Additional Reading 217
 Appendices 218
 Appendix 6.1 Estimating the Future Increases in
 World Population 218
 Appendix 6.2 Cartagena Protocol on Biosafety: Risk
 Assessment 220
 Problem Set 222

7 Medical Ethics 223

Background 223
 General Medical Ethics 224
 Codes of Professional Conduct 224
 Patients' Rights to Information 224
 Confidentiality 226
 Responsibilities of the Physician Regarding
 Disclosure of Patient Information 228
 Ownership of Medical Information 228
 Refusal of Treatment 229
 Ethics of Rendering Medical Aid 231
 When Options for Continuing Care Conflict with a
 Physician's Ethics 234
 Ethics of Medical Mistakes 234
 Physician Conflicts of Interest 235
 The Ethics of Futile Care 237
 Use of Medical Marijuana 239
 The Ethics of Dying 240
 Who Decides on Life Support and Death? 241
 Advance Health Care Directives 243
 Arguments against Advance Health Care
 Directives 247
 Sacrifice of One Life to Save Another 247
 Physician-Assisted Suicide 249
 Summary of the Ethics of Physician-Assisted
 Suicide 253

Resource Allocation and Organ Transplantation 253
 Ways to Maximize the Availability of Scarce
 Resources 256
 Ethical Considerations of Organ Transplantation 257
 Use of Fetal Tissues 257
 Transplantation Procedures for Prisoners 258
 Buying and Selling of Body Tissues and
 Organs 258
 Distribution of Care When Resources Are
 Limited 259
 Treatment in Situations of Extreme Illness 261
 Human Experimentation and Animal
 Experimentation 262
 Chapter Summary 262
 References 262
 Additional Reading 265
 Appendices 265

Appendix 7.1 California Advance Health Care
 Directive. 265
 (California Probate Code Section 4701) 265
 Appendix 7.2: Organ Transplantation Evaluation by
 Institute of Medicine 273
 Appendix 7.3 AMA Section E-2.03 Allocation of
 Limited Medical Resources 274
 Problem Set 274

**8 Ethics of Human and Animal
 Experimentation 277**

Ethics of Human Experimentation 277
 Background 277
 Current Guidelines for Research on Human
 Beings 279
 IRB Duties 279
 IRB Composition 280
 Guidelines for IRB Activities 281
 Informed Consent Procedures 282
 Variety of Human Experiments 284
 Proposed Modifications of Regulations on Protection
 for Human Subjects Involved in Medical
 Research 285
 Noted Examples of Human Experimentation 287
 Summary of Human Experimentation 288

Ethics of Animal Experimentation	289
Cultural Attitudes toward Animals	289
Animal Malfeasance vs. Medical Benefits	290
Federal Regulations	292
Reduction in the Need for Animals	294
Microarray and Phage Array Technologies	294
Animal Imaging Technologies	295
Transgenic Animals	296
Summary of Issues in Animal Experimentation	297
Chapter Summary	297
References	298
Additional Reading	299
Appendix	299
Appendix 8.1 Office of Human Research Protection (OHRP) Informed Consent Checklist—Basic and Additional Elements of the Consent Form for Research Subjects	299
Problem Set	300

9 Ethics of Assisted Reproductive Technologies 303

Introduction	303
Types of ART	304
In Vitro Fertilization	304
Preimplantation Genetic Diagnosis (PGD)	307
Polar Body Analysis	308
Embryo Biopsy	308
Success Rates of ART	310
Risks of ART	311
Regulation of ART in the United States	316
Ethical Concerns about ART	316
The Ethics of IVF	317
Ethical Issues of PGD	320
Cloning	322
Reproductive Cloning	322
Reproductive and Therapeutic Cloning Differences	324
Experience with Reproductive Cloning in Animals	325

Ethical Issues Surrounding Reproductive and Therapeutic Cloning	326
Ethical Issues Surrounding Reproductive Cloning	326
Arguments for Reproductive Cloning	327
Arguments against Reproductive Cloning	328
Justice and Fairness in the Cloning Debate	329
Chapter Summary	331
References	332
Additional Reading	335
Appendices	336
Appendix 9.1	336
Appendix 9.2	338
Problem Set	340

10 Ethics of Stem Cell Technologies 342

Introduction	342
Background	342
Types of Stem Cells and Their Origins	344
Embryonic Stem (ES) Cells	344
Alternative Sources of Embryonic Stem Cells	347
Embryonic Germ (EG) Cells	348
Adult Stem Cells	348
Hematopoietic Stem Cells	349
Cord-Blood Stem Cells	350
Current Status of Embryonic Stem Cell Research	350
Status of Adult Stem Cell Research	356
Hematopoietic Stem Cell Transplantation	357
Neurogenesis	358
Myogenesis	360
Heart Muscle Regeneration	360
Liver Regeneration	364
Pancreas Regeneration	364
Lung Renewal	364
Summary of Technical Status of Adult Stem Cell Research	364
Ethical Issues in Embryonic Stem Cell Research and Therapy	366
Chapter Summary	374
References	376
Additional Reading	381
Problem Set	381

11 Ethics of Enhancement Technologies 383

Introduction	383
Preimplantation Genetic Diagnosis	385
Ethical Implications of PGD	385
Gene Therapy	386
Overview of Uses for Enhancement and Methodology	386
Somatic Gene Therapy	389
Gene Therapy for Severe Combined Immunodeficiency with Adenosine Deaminase Deficiency (ADA-SCID)	390
Children Undergoing Gene Therapy for X-Linked SCID	391
History of Gene Therapy	392
Gene Therapy for Parkinson's Disease	393
Gene Therapy for Hemophilia	394
Somatic Gene Therapy for Human Enhancement	395
Gene Therapy to Enhance Muscle Strength	395
<i>In Utero</i> Somatic Gene Therapy	396
Regulation of Somatic Gene Therapy	397
Current Status and Future Plans for Human Gene Therapy	397
Ethical Issues of Somatic Gene Therapy for Enhancement	398
Germline Gene Therapy	400
Methodology of Proposed Germline Gene Therapy	400
Ethical Issues of Germline Gene Therapy	401
Arguments for Germline Gene Therapy	402
Arguments against Germline Gene Therapy	403
Oversight for Germline Engineering	404
Enhancement by Drugs or Other Means	405
Drug Use to Enhance Performance in Sport	405
Background	405
History of Drug Use in Modern Sport	406
Substances Used to Enhance Performance (Doping)	406
Caffeine	407
Ephedrine, Phenylephrine, Epinephrine, and Ephedra and other Alpha-Adrenergic Drugs	408
Amphetamines and Methylphenidate (Ritalin)	409
Growth Hormone	409

Diuretics	410
Erythropoietin (EPO)	411
Tetrahydrogestrinone (THG)	411
Creatine and Androstenidione	412
Reasons Athletes Use Drugs	414
Prevalence of Doping	414
Enhancement of Behavior through Drugs	415
Body Enhancement by Surgery	417
Ethics of Behavioral and Physical Enhancements	418
Ethical Duties of the Medical Practitioner	419
Chapter Summary	420
References	422
Additional Reading	427
Appendix 11.1	427
Problem Set	431

12 Ethics of Emerging Technologies 433

Introduction	433
Risk Analysis and Cost-Benefit Analysis	437
Cost-Benefit Analysis (CBA)	442
Nanotechnology	444
Synthetic Biology	445
Ethics of Emerging Threats of Terrorism	447
Neuroenhancements and Neuroengineering	448
Deep Brain Stimulation	449
Brain-Computer Interfacing	450
Regenerative and Rehabilitative Neurology	451
Brain Imaging	452
Psychopharmacology	454
Ethics of Human Space Exploration	454
Ethics in Colonization of the Moon and Mars	456
The Role of Government in Evaluating the Risks of New Technologies	458
Chapter Summary	460
References	461
Additional Reading	464
Problem Set	464

Glossary 466

Index 477